NCT07132333

Molecular Inflammation Board at the Center for Personalized Medicine

The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Molecular Inflammation Board at the Center for Personalized Medicine

Detailed description

Molecular Inflammation Board at the Center for Personalized Medicine The study objectives are: To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care

Conditions

• Psoriasis (PsO)
• Psoriasis Arthritis
• Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
• Spondylarthropathies

Interventions

Type	Name	Description
BIOLOGICAL	Biologic Agent	Intervention with biologic agents

Timeline

• Start date: 2022-11-16
• Primary completion: 2032-11-01
• Completion: 2032-11-01
• First posted: 2025-08-20
• Last updated: 2025-08-20

Locations

1 site across 1 country: Germany